Clinical Reviews in Allergy & Immunology

, Volume 34, Issue 1, pp 26–31 | Cite as

Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?

  • Zoltán SzekaneczEmail author
  • Lilla Soós
  • Zoltán Szabó
  • Andrea Fekete
  • Anikó Kapitány
  • Anikó Végvári
  • Sándor Sipka
  • Gabriella Szücs
  • Sándor Szántó
  • Gabriella Lakos


Anti-citrullinated protein antibodies (ACPAs) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. The first members of this autoantibody family were anti-perinuclear factor (APF) and anti-keratin antibodies (AKA). It became evident that both APF and AKA recognize citrullinated epitopes of filaggrin. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets for anti-filaggrin antibodies led to the development of the first and later second generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The widely used anti-CCP2 assays have high diagnostic sensitivity and specificity, and they also show important predictive and prognostic value in RA. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin, hence it is a new member of the family of ACPAs. The newly developed anti-mutated citrullinated vimentin (anti-MCV) assay has similar diagnostic performance than the anti-CCP2 ELISA; however, the diagnostic spectrum of the anti-MCV test is somewhat different from that of anti-CCP2. It’s especially useful in the diagnosis of RA in RF and anti-CCP2 seronegative patients. The combined application of anti-CCP2 and anti-MCV assays can improve the laboratory diagnostics of RA. The family of ACPAs is expected to expand; there is an increasing need for developing new diagnostic strategies after careful evaluation of the characteristics of the available assays.


Rheumatoid arthritis Anti-mutated citrullinated vimentin Anti-CCP2 



This work was supported by grant no. T 048541 from the Hungarian National Scientific Research Fund (OTKA; Z.S.).


  1. 1.
    Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4:130–136PubMedCrossRefGoogle Scholar
  2. 2.
    Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903–911PubMedCrossRefGoogle Scholar
  3. 3.
    Goldblatt F, Isenberg DA (2005) New therapies for rheumatoid arthritis. Clin Exp Immunol 140:195–204PubMedCrossRefGoogle Scholar
  4. 4.
    Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS (1993) Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 32:199–203PubMedCrossRefGoogle Scholar
  5. 5.
    Deprés N, Boire G, Lopez-Longo FJ, Ménard HA (1994) The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 21:1027–1033Google Scholar
  6. 6.
    Nienhuis RLF, Mandema EA (1964) A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 23:302–305PubMedGoogle Scholar
  7. 7.
    Van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC (1993) The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 32:546–549PubMedCrossRefGoogle Scholar
  8. 8.
    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236–243PubMedCrossRefGoogle Scholar
  9. 9.
    Visser H, Gelinck LB, Kampfraath AH, Beedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157–161PubMedGoogle Scholar
  10. 10.
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRefGoogle Scholar
  11. 11.
    Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594PubMedGoogle Scholar
  12. 12.
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRefGoogle Scholar
  13. 13.
    Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99PubMedCrossRefGoogle Scholar
  14. 14.
    Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393PubMedGoogle Scholar
  15. 15.
    Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, Fournie B, Mazieres B, Serre G (1998) Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol 25:838–846PubMedGoogle Scholar
  16. 16.
    Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, Rolland D, Fournie B, Cantagrel A, Jolivet M, Serre G (2002) Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 46:2051–2058PubMedCrossRefGoogle Scholar
  17. 17.
    van der Helm-van Mil AH, Wesoly JZ, Huizinga TW (2005) Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17:299–304PubMedCrossRefGoogle Scholar
  18. 18.
    van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121PubMedCrossRefGoogle Scholar
  19. 19.
    Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433–3438PubMedCrossRefGoogle Scholar
  20. 20.
    Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25:1106–1118PubMedCrossRefGoogle Scholar
  21. 21.
    Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, Barrera P, Zendman AJ, van Venrooij WJ (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373–381PubMedCrossRefGoogle Scholar
  22. 22.
    Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44:40–50CrossRefGoogle Scholar
  23. 23.
    Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494PubMedCrossRefGoogle Scholar
  24. 24.
    Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, Yamamoto K (2006) Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 65:1013–1020PubMedCrossRefGoogle Scholar
  25. 25.
    Asaga H, Yamada M, Senshu T (1998) Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 243:641–646PubMedCrossRefGoogle Scholar
  26. 26.
    Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nature Cell Biol 5:59–63PubMedCrossRefGoogle Scholar
  27. 27.
    Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166:4177–4184PubMedGoogle Scholar
  28. 28.
    Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, Roudier, Serre G (2006) Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36:2250–2263PubMedCrossRefGoogle Scholar
  29. 29.
    Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44:1374–1382PubMedCrossRefGoogle Scholar
  30. 30.
    Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyse F (2001) Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 44:2255–2262PubMedCrossRefGoogle Scholar
  31. 31.
    Chapuy-Regaud S, Sebbag M, Baeten D, Clavel C, Foulquier C, De Keyser F, Serre G (2005) Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol 174:5057–5064PubMedGoogle Scholar
  32. 32.
    Van Esch WJ, Reparon-Schuijt CC, Hamstra HJ, Van Kooten C, Logtenberg T, Breedveld FC, Verweij CL (2003) Human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis show the imprints of an antigen-dependent process of somatic hypermutation and clonal selection. Clin Exp Immunol 131:364–376PubMedCrossRefGoogle Scholar
  33. 33.
    Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, Durroux R, Cantagrel A, Serre G (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119:544–552PubMedCrossRefGoogle Scholar
  34. 34.
    Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, Breedveld FC, Verweij CL (2001) Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 44:41–47PubMedCrossRefGoogle Scholar
  35. 35.
    Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, Zendman AJ, Harris HE (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7:R458–R467PubMedCrossRefGoogle Scholar
  36. 36.
    Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116:961–973PubMedCrossRefGoogle Scholar
  37. 37.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRefGoogle Scholar
  38. 38.
    van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54:1117–1121PubMedCrossRefGoogle Scholar
  39. 39.
    Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F (2005) Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 52:3813–3818PubMedCrossRefGoogle Scholar
  40. 40.
    Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365PubMedCrossRefGoogle Scholar
  41. 41.
    Kapitány A, Szabó Z, Lakos G, Aleksza M, Végvári A, Soós L, Karányi Z, Sipka S, Szegedi G, Szekanecz Z (2006) Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in patients with rheumatoid arthritis. Ann Rheum Dis 65(Suppl II):299Google Scholar
  42. 42.
    Roudier J (2000) Association of MHC and rheumatoid arthritis. Association of RA with HLA-DR4: the role of repertoire selection. Arthritis Res 2:217–220PubMedCrossRefGoogle Scholar
  43. 43.
    Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541PubMedGoogle Scholar
  44. 44.
    Klareskog L, Padyukov L, Lorentzen J, Alfredsson L (2006) Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nature Clin Pract Rheumatol 2:425–433CrossRefGoogle Scholar
  45. 45.
    Smolen JS (1996) Autoantibodies in rheumatoid arthritis. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of disease. Kluwer, Dordrecht, pp 1–18Google Scholar
  46. 46.
    Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679PubMedGoogle Scholar
  47. 47.
    Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393PubMedCrossRefGoogle Scholar
  48. 48.
    Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, Heikkila R, Nykanen M, von Essen R (1998) Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 115:294–302PubMedCrossRefGoogle Scholar
  49. 49.
    Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, von Essen R (1999) Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 28:113–116PubMedCrossRefGoogle Scholar
  50. 50.
    Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRefGoogle Scholar
  51. 51.
    Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRefGoogle Scholar
  52. 52.
    Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRefGoogle Scholar
  53. 53.
    Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42:677–680CrossRefGoogle Scholar
  54. 54.
    Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRefGoogle Scholar
  55. 55.
    Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089PubMedCrossRefGoogle Scholar
  56. 56.
    Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50:3776–3782PubMedCrossRefGoogle Scholar
  57. 57.
    Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G (2005) Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 38:17–24PubMedCrossRefGoogle Scholar
  58. 58.
    Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRefGoogle Scholar
  59. 59.
    Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, Benali K, Eliaou JF, Kahn MF, Sany J, Meyer O (1999) Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 26:7–13PubMedGoogle Scholar
  60. 60.
    Menard HA, Lapointe E, Rochdi MD, Zhou ZJ (2000) Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2:429–432PubMedCrossRefGoogle Scholar
  61. 61.
    Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, Carrier N, Daniel C, Menard HA (2005) Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are notequivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603PubMedCrossRefGoogle Scholar
  62. 62.
    Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Menard HA (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150PubMedCrossRefGoogle Scholar
  63. 63.
    Lakos G, Soos L, Szabo Z, Fekete A, Zeher M, Horváth I, Dankó K, Kapitány A, Szegedi G, Sipka S, Szekanecz Z (2006) Antibodies directed against mutated citrullinated vimentin (anti-MCV) are more sensitive serological markers of rheumatoid arthritis than anti-CCP. Ann Rheum Dis 65(Suppl II):151Google Scholar
  64. 64.
    Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8:R119PubMedCrossRefGoogle Scholar
  65. 65.
    Rodriguez-Mahou M, López-Longo FJ, Sanchez-Ramon S, Estecha A, Garcia-Segovia A, Rodriguez-Molina JJ, Carreno L, Fernandez-Cruz E (2006) Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis. Arthritis Care Res 55:657–661CrossRefGoogle Scholar
  66. 66.
    Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA (2006) Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 33:2115–2119PubMedGoogle Scholar
  67. 67.
    Vander Cruyssen B, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 8:R122CrossRefGoogle Scholar
  68. 68.
    Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204PubMedCrossRefGoogle Scholar
  69. 69.
    Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J (2005) Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52:3424–3432PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Zoltán Szekanecz
    • 1
    Email author
  • Lilla Soós
    • 1
  • Zoltán Szabó
    • 1
  • Andrea Fekete
    • 2
  • Anikó Kapitány
    • 2
  • Anikó Végvári
    • 1
  • Sándor Sipka
    • 2
  • Gabriella Szücs
    • 1
  • Sándor Szántó
    • 1
  • Gabriella Lakos
    • 2
  1. 1.Division of Rheumatology, 3rd Department of Medicine, Medical and Health Science CenterUniversity of DebrecenDebrecenHungary
  2. 2.Laboratory of Immunology, 3rd Department of Medicine, Medical and Health Science CenterUniversity of DebrecenDebrecenHungary

Personalised recommendations